Man Group PLC Travere Therapeutics, Inc. Transaction History

Man Group PLC

$37.2 Billion
Q1 2025

A detailed history of Man Group PLC transactions in Travere Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 48,779 shares of TVTX stock, worth $727,294. This represents 0.0% of its overall portfolio holdings.

Number of Shares

48,779

Previous 88,241 44.72%

Holding current value

$727,294

Previous $1.54 Million 43.14%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$17.07 - $23.75 $673,616 - $937,222	-39,462 Reduced 44.72%	48,779 $874,000
Q4 2024 Feb 14, 2025	BUY	$13.65 - $19.85 $857,192 - $1.25 Million	62,798 Added 246.82%	88,241 $1.54 Million
Q3 2024 Nov 14, 2024	SELL	$7.89 - $15.21 $577,697 - $1.11 Million	-73,219 Reduced 74.21%	25,443 $355,000
Q2 2024 Aug 14, 2024	SELL	$5.26 - $8.28 $99,619 - $156,814	-18,939 Reduced 16.1%	98,662 $811,000
Q1 2024 May 15, 2024	BUY	$7.18 - $9.82 $844,375 - $1.15 Million	117,601 New	117,601 $906,000
Q1 2023 May 15, 2023	SELL	$17.82 - $22.89 $49,896 - $64,092	-2,800 Reduced 13.15%	18,500 $416,000
Q4 2022 Feb 14, 2023	BUY	$18.47 - $26.14 $51,716 - $73,192	2,800 Added 15.14%	21,300 $447,000
Q3 2022 Nov 14, 2022	BUY	$22.91 - $28.63 $423,835 - $529,655	18,500 New	18,500 $456,000
Q2 2022 Aug 15, 2022	SELL	$20.94 - $30.01 $198,930 - $285,095	-9,500 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$23.61 - $30.6 $224,295 - $290,700	9,500 New	9,500 $245,000
Q1 2021 May 17, 2021	SELL	$23.37 - $31.77 $1.26 Million - $1.71 Million	-53,777 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$19.17 - $27.87 $1.03 Million - $1.5 Million	53,777 New	53,777 $1.47 Million

Others Institutions Holding TVTX

# of Institutions

239

Shares Held

99.9M

Call Options Held

1.79M

Put Options Held

555K

View Full List

About Travere Therapeutics, Inc.

Ticker TVTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 64,173,600
Market Cap $957M
Description
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic a...

More about TVTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.

Account